Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 2/2008

01-01-2008 | Original paper

The burden of rheumatoid arthritis and access to treatment: determinants of access

Authors: J. Lundqvist, F. Kastäng, G. Kobelt, B. Jönsson

Published in: The European Journal of Health Economics | Special Issue 2/2008

Login to get access

Abstract

As part of the study “The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment”, this paper reviews the impact on access to RA drugs of the approval processes, pricing and funding decisions and times to market (access) in different countries. In addition, an overview of health technology assessments (HTA) and the economic literature related to RA treatments is provided. The time from approval to market access ranged from immediate to over 500 days in the countries included in the study. A total of 55 HTA reports were identified, 40 of them in the period between 2002 and 2006; 29 were performed by European HTA agencies, 14 in Canada and 7 in the United States. A total of 239 economic evaluations related to RA were identified in a specialized health economic database (HEED).
Literature
1.
Magnusson, S.: Treatment of rheumatoid arthritis—does it affect society’s cost for the disease? Br. J. Rheumatol. 35, 791–795 (1996)CrossRef
2.
3.
DiMasi, J.A., Hansen, R.W., Grabowski, H.G., Lasagna, L.: Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107–142 (1991)CrossRef
4.
DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003)CrossRef
5.
Adams, C.P., Brantner, V.V.: Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 25, 420–428 (2006)CrossRef
6.
Motola, D., De Ponti, F., Poluzzi, E., et al.: An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 62, 610–616 (2006)CrossRef
7.
8.
9.
Health Canada (2005) Priority review of drug submissions. Guidance Date 30 11 2005
10.
11.
Danzon, P.M., Furukawa, M.F.: Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) (Suppl) Web Exclus. W3:521–536 (2003)
12.
Pharmaceutical Price Controls in OECD Countries (2004) Implications of U.S. Consumers, Pricing, Research and Development, and Innovation. U.S. Department of Commerce International Trade Administration, Washington, DC
13.
Patients W.A.I.T. Indicator (2007) Phase 6 Report. IMS Management Consulting
14.
National Institute for Clinical Excellence (2002) Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technol. Appraisal no. 36 (March)
15.
Sundhedsstyrelsen Center for Evaluering og Medicinsk Teknologivurdering. Rheumatoid Arthritis (2002) Health Technology Assessment of diagnosis and treatment. Medicinsk Teknologivurdering 4
16.
Coyle, D., Judd, M., Blumenauer, B., et al.: Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation (Technology report no 64). Canadian Coordinating Office for Health Technology Assessment, Ottawa (2006)
17.
National Institute for Clinical Excellence (2003) Anakinra for rheumatoid arthritis. Technol. Appraisal 72 (November)
Metadata
Title
The burden of rheumatoid arthritis and access to treatment: determinants of access
Authors
J. Lundqvist
F. Kastäng
G. Kobelt
B. Jönsson
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue Special Issue 2/2008
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-007-0090-1

Other articles of this Special Issue 2/2008

The European Journal of Health Economics 2/2008 Go to the issue

Original paper

The burden of rheumatoid arthritis and access to treatment: health burden and costs

Original paper

The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments

Original paper

Patient access to rheumatoid arthritis treatments

Original paper

The burden of rheumatoid arthritis and access to treatment: a medical overview

Editorial

Patient access to rheumatoid arthritis treatments

Original paper

The burden of rheumatoid arthritis and access to treatment: uptake of new therapies